Clinical standards for the management of adverse effects during treatment for TB

doi:10.5588/ijtld.23.0078

. 2023 Jul 1;27(7):506-519.

doi: 10.5588/ijtld.23.0078.

Clinical standards for the management of adverse effects during treatment for TB

K P Singh¹, A C C Carvalho², R Centis³, L D Ambrosio⁴, G B Migliori³, S G Mpagama⁵, B C Nguyen⁶, R E Aarnoutse⁷, A Aleksa⁸, R van Altena⁹, P K Bhavani¹⁰, M S Bolhuis¹¹, S Borisov¹², N van T Boveneind-Vrubleuskaya¹³, J Bruchfeld¹⁴, J A Caminero¹⁵, I Carvalho¹⁶, J G Cho¹⁷, L Davies Forsman¹⁸, M Dedicoat¹⁹, K Dheda²⁰, K Dooley²¹, J Furin²², J M García-García²³, A Garcia-Prats²⁴, A C Hesseling²⁵, S K Heysell²⁶, Y Hu²⁷, H Y Kim²⁸, S Manga²⁹, B J Marais³⁰, I Margineanu¹¹, A-G Märtson³¹, M Munoz Torrico³², H M Nataprawira³³, E Nunes³⁴, C W M Ong³⁵, R Otto-Knapp³⁶, D J Palmero³⁷, C A Peloquin³⁸, A Rendon³⁹, D Rossato Silva⁴⁰, R Ruslami⁴¹, A M I Saktiawati⁴², P Santoso⁴³, H S Schaaf²⁵, B Seaworth⁴⁴, U S H Simonsson⁴⁵, R Singla⁴⁶, A Skrahina⁴⁷, I Solovic⁴⁸, S Srivastava⁴⁹, S L Stocker⁵⁰, M G G Sturkenboom¹¹, E M Svensson⁵¹, M Tadolini⁵², T A Thomas²⁶, S Tiberi⁵³, J Trubiano⁵⁴, Z F Udwadia⁵⁵, A R Verhage⁵⁶, D H Vu⁵⁷, O W Akkerman⁵⁸, J W C Alffenaar²⁸, J T Denholm

Affiliations

¹ Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Victorian Infectious Disease Unit, Royal Melbourne Hospital, VIC, Australia.
² Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
³ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
⁴ Public Health Consulting Group, Lugano, Switzerland.
⁵ Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania, Kibong´oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania.
⁶ Woolcock Institute of Medical Research, Viet Nam and University of Sydney, NSW, Australia.
⁷ Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
⁸ Grodno State Medical University, Grodno, Belarus.
⁹ Asian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM), Yangon, Myanmar.
¹⁰ Indian Council of Medical Research-National Institute for Research in Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
¹¹ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
¹² Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia.
¹³ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands.
¹⁴ Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
¹⁵ Department of Pneumology. University General Hospital of Gran Canaria "Dr Negrin", Las Palmas, Spain, ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain.
¹⁶ Paediatric Department, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia, Portugal.
¹⁷ Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Parramatta Chest Clinic, Parramatta, NSW, Australia.
¹⁸ Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
¹⁹ Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
²⁰ Centre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa, South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
²¹ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
²² Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
²³ Tuberculosis Research Programme, SEPAR (Sociedad Española de Neumología y Cirugía Torácica), Barcelona, Spain.
²⁴ Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa, Department of Pediatrics, University of Wisconsin, Madison, WI, USA.
²⁵ Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
²⁶ Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
²⁷ Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
²⁸ Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
²⁹ Tuberculosis Department Latin American Society of Thoracic Diseases, Lima, Peru.
³⁰ Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Department of Infectious Diseases and Microbiology, The Children´s Hospital at Westmead, Westmead, NSW, Australia.
³¹ Centre of Excellence in Infectious Diseases Research, Antimicrobial Pharmacodynamics and Therapeutics Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
³² Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, México City, Mexico.
³³ Division of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
³⁴ Department of Pulmonology of Central Hospital of Maputo, Maputo, Mozambique, Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique.
³⁵ Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy, Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.
³⁶ German Central Committee Against Tuberculosis (DZK), Berlin, Germany.
³⁷ Hospital Muniz and Instituto Vaccarezza, Buenos Aires, Argentina.
³⁸ Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
³⁹ Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Neumología, CIPTIR, Monterrey, Mexico.
⁴⁰ Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
⁴¹ TB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
⁴² Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia, Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
⁴³ Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.
⁴⁴ University of Texas Health Science Center at Tyler, Tyler, TX, USA.
⁴⁵ Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
⁴⁶ Department of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India.
⁴⁷ Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
⁴⁸ National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ružomberok, Vyšné Hágy, Slovakia.
⁴⁹ University of Texas Health Science Center at Tyler, Tyler, TX, USA, Department of Medicine, The University of Texas at Tyler School of Medicine, TX, USA, Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, TX, USA.
⁵⁰ School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Department of Clinical Pharmacology and Toxicology, St Vincent´s Hospital, Sydney, NSW, Australia.
⁵¹ Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
⁵² Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant´Orsola, Bologna, Italy, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
⁵³ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁵⁴ Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Department of Infectious Diseases, Austin Hospital, Melbourne, VIC, Australia.
⁵⁵ P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
⁵⁶ Department of Paediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
⁵⁷ National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam.
⁵⁸ Department of Pulmonary Diseases and Tuberculosis, Groningen, Haren, the Netherlands, Tuberculosis Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, the Netherlands.

PMID: 37353868
PMCID: PMC10321364
DOI: 10.5588/ijtld.23.0078

Clinical standards for the management of adverse effects during treatment for TB

K P Singh et al. Int J Tuberc Lung Dis. 2023.

. 2023 Jul 1;27(7):506-519.

doi: 10.5588/ijtld.23.0078.

Authors

Affiliations

¹ Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Victorian Infectious Disease Unit, Royal Melbourne Hospital, VIC, Australia.
² Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
³ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
⁴ Public Health Consulting Group, Lugano, Switzerland.
⁵ Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania, Kibong´oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania.
⁶ Woolcock Institute of Medical Research, Viet Nam and University of Sydney, NSW, Australia.
⁷ Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
⁸ Grodno State Medical University, Grodno, Belarus.
⁹ Asian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM), Yangon, Myanmar.
¹⁰ Indian Council of Medical Research-National Institute for Research in Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
¹¹ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
¹² Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia.
¹³ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands.
¹⁴ Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
¹⁵ Department of Pneumology. University General Hospital of Gran Canaria "Dr Negrin", Las Palmas, Spain, ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain.
¹⁶ Paediatric Department, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia, Portugal.
¹⁷ Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Parramatta Chest Clinic, Parramatta, NSW, Australia.
¹⁸ Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
¹⁹ Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
²⁰ Centre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa, South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
²¹ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
²² Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
²³ Tuberculosis Research Programme, SEPAR (Sociedad Española de Neumología y Cirugía Torácica), Barcelona, Spain.
²⁴ Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa, Department of Pediatrics, University of Wisconsin, Madison, WI, USA.
²⁵ Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
²⁶ Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
²⁷ Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
²⁸ Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
²⁹ Tuberculosis Department Latin American Society of Thoracic Diseases, Lima, Peru.
³⁰ Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Department of Infectious Diseases and Microbiology, The Children´s Hospital at Westmead, Westmead, NSW, Australia.
³¹ Centre of Excellence in Infectious Diseases Research, Antimicrobial Pharmacodynamics and Therapeutics Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
³² Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, México City, Mexico.
³³ Division of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
³⁴ Department of Pulmonology of Central Hospital of Maputo, Maputo, Mozambique, Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique.
³⁵ Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy, Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.
³⁶ German Central Committee Against Tuberculosis (DZK), Berlin, Germany.
³⁷ Hospital Muniz and Instituto Vaccarezza, Buenos Aires, Argentina.
³⁸ Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
³⁹ Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Neumología, CIPTIR, Monterrey, Mexico.
⁴⁰ Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
⁴¹ TB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
⁴² Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia, Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
⁴³ Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.
⁴⁴ University of Texas Health Science Center at Tyler, Tyler, TX, USA.
⁴⁵ Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
⁴⁶ Department of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India.
⁴⁷ Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
⁴⁸ National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ružomberok, Vyšné Hágy, Slovakia.
⁴⁹ University of Texas Health Science Center at Tyler, Tyler, TX, USA, Department of Medicine, The University of Texas at Tyler School of Medicine, TX, USA, Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, TX, USA.
⁵⁰ School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Department of Clinical Pharmacology and Toxicology, St Vincent´s Hospital, Sydney, NSW, Australia.
⁵¹ Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
⁵² Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant´Orsola, Bologna, Italy, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
⁵³ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁵⁴ Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Department of Infectious Diseases, Austin Hospital, Melbourne, VIC, Australia.
⁵⁵ P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
⁵⁶ Department of Paediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
⁵⁷ National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam.
⁵⁸ Department of Pulmonary Diseases and Tuberculosis, Groningen, Haren, the Netherlands, Tuberculosis Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, the Netherlands.

PMID: 37353868
PMCID: PMC10321364
DOI: 10.5588/ijtld.23.0078

Abstract
in English, French

BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.

CONTEXTE :: Les effets indésirables (AE) du traitement de la TB sont une cause de morbidité, de mortalité et d’interruption du traitement. L’objectif de ces normes cliniques est d’encourager une meilleure pratique en matière de diagnostic et de prise en charge des AE.

MÉTHODES :: Ont participé 65/81 experts invités à un processus Delphi utilisant une échelle de Likert en 5 points pour évaluer des ébauches de normes.

RÉSULTATS :: Nous avons identifié huit normes cliniques. Chaque personne commençant un traitement antituberculeux devrait : Norme 1, être informée des AE avant et pendant le traitement ; Norme 2, être évaluée afin de détecter tout facteur susceptible d’augmenter le risque d’AE et faire l’objet d’un examen régulier afin d’identifier et de prendre en charge ces facteurs de manière proactive ; Norme 3, en cas d’AE, être évaluée avec soin et tenir compte d’éventuelles réactions allergiques ou d’hypersensibilité ; Norme 4, recevoir des soins appropriés pour minimiser la morbidité et la mortalité associées aux AE ; Norme 5, reprendre les médicaments antituberculeux après un AE grave selon un protocole standardisé avec une surveillance active de l’innocuité des médicaments ; Norme 6, les agents de santé doivent être formés aux AE, y compris à la manière de conseiller les personnes qui suivent un traitement antituberculeux, ainsi qu’à la surveillance et à la prise en charge actives des AE ; Norme 7 : tous les nouveaux médicaments et schémas antituberculeux doivent faire l’objet d’une surveillance active des AE et d’une notification ; et Norme 8 : les lacunes en matière de connaissances identifiées grâce à la surveillance active des AE doivent être systématiquement comblées par la recherche clinique.

CONCLUSION :: Ces normes fournissent une approche centrée sur la personne et fondée sur le consensus afin de minimiser l’impact des AE pendant le traitement de la TB.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: CWMO received speaking fees from Qiagen (Hilden, Germany) outside the context of this work.

Cited by

Standards for clinical trials for treating TB.
du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. du Cros P, et al. Int J Tuberc Lung Dis. 2023 Dec 1;27(12):885-898. doi: 10.5588/ijtld.23.0341. Int J Tuberc Lung Dis. 2023. PMID: 38042969 Free PMC article.
Bioassay-guided isolation and structure elucidation of anti-mycobacterium tuberculosis compounds from Galatella grimmii (Regel & Schmalh.) Sennikov.
Shakeri A, Tajvar M, Tabrizi GT, Soleimanpour S, Davoodi J, Asili J, Amiri MS, Emami SA. Shakeri A, et al. BMC Complement Med Ther. 2024 Oct 1;24(1):345. doi: 10.1186/s12906-024-04632-w. BMC Complement Med Ther. 2024. PMID: 39354550 Free PMC article.
Decentralised ECG monitoring for drug-resistant TB patients in ambulatory settings.
Mbenga M, Slyzkyi A, Mirtskhulava V, Pak S, Gebhard A, Utepkalieva G, Sagimbekova A, Adenov M, Ryskulov G. Mbenga M, et al. IJTLD Open. 2024 Apr 1;1(4):192-194. doi: 10.5588/ijtldopen.23.0623. eCollection 2024 Apr. IJTLD Open. 2024. PMID: 38988404 Free PMC article. No abstract available.
Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.
Visca D, Centis R, Pontali E, Zampogna E, Russell AM, Migliori GB, Andrejak C, Aro M, Bayram H, Berkani K, Bruchfeld J, Chakaya JM, Chorostowska-Wynimko J, Crestani B, Dalcolmo MP, D'Ambrosio L, Dinh-Xuan AT, Duong-Quy S, Fernandes C, García-García JM, de Melo Kawassaki A, Carrozzi L, Martinez-Garcia MA, Martins PC, Mirsaeidi M, Mohammad Y, Naidoo RN, Neuparth N, Sese L, Silva DR, Solovic I, Sooronbaev TM, Spanevello A, Sverzellati N, Tanno L, Tiberi S, Vasankari T, Vasarmidi E, Vitacca M, Annesi-Maesano I. Visca D, et al. Int J Tuberc Lung Dis. 2023 Oct 1;27(10):729-741. doi: 10.5588/ijtld.23.0248. Int J Tuberc Lung Dis. 2023. PMID: 37749839 Free PMC article.
Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa.
Gaida R, Davids AS, Sewpaul R. Gaida R, et al. S Afr J Infect Dis. 2023 Dec 19;38(1):564. doi: 10.4102/sajid.v38i1.564. eCollection 2023. S Afr J Infect Dis. 2023. PMID: 38223433 Free PMC article.

See all "Cited by" articles

References

1. Nahid P, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. - PMC - PubMed
1. World Health Organisation. Geneva, Switzerland: WHO; 2020. Consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. - PubMed
1. World Health Organisation Geneva, Switzerland: WHO; 2022. Consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-susceptible tuberculosis treatment. - PubMed
1. Pradipta IS, et al. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018;77(6):469–478. - PubMed
1. Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ. 2008;86(3):B–D. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Nahid P, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. - PMC - PubMed

[2] Nahid P, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. - PMC - PubMed

[3] World Health Organisation. Geneva, Switzerland: WHO; 2020. Consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. - PubMed

[4] World Health Organisation. Geneva, Switzerland: WHO; 2020. Consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. - PubMed

[5] World Health Organisation Geneva, Switzerland: WHO; 2022. Consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-susceptible tuberculosis treatment. - PubMed

[6] World Health Organisation Geneva, Switzerland: WHO; 2022. Consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-susceptible tuberculosis treatment. - PubMed

[7] Pradipta IS, et al. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018;77(6):469–478. - PubMed

[8] Pradipta IS, et al. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018;77(6):469–478. - PubMed

[9] Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ. 2008;86(3):B–D. - PMC - PubMed

[10] Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ. 2008;86(3):B–D. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical standards for the management of adverse effects during treatment for TB

Affiliations

Clinical standards for the management of adverse effects during treatment for TB

Authors

Affiliations

Abstract
in English, French

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract in English, French

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract
in English, French